Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis

优化皮肤利什曼病的监测和治疗控制

基本信息

批准号：
9897617
负责人：
Nancy Gore Saravia
金额：
$ 55.27万
依托单位：
CENTRO INTERNACIONAL (CIDEIM)
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-15 至 2022-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9897617
关键词：
Address Adherence Affect Area Bioinformatics Biological Markers Biopsy Blood Cells Cellular biology Clinical Clinical Trials Colombia Communities Cryopreservation Cutaneous Cutaneous Leishmaniasis Data Data Collection Detection Development Diagnosis Drug Exposure Drug resistance Effectiveness Epidemiology Evaluation Expression Profiling Failure Foundations Gene Expression Profiling Genetic Markers Genomics Goals Host Defense Mechanism Immunology Impairment In Vitro Inflammatory Inflammatory Response International Intervention Knowledge Latin American Leishmania Leishmaniasis Lesion Maps Modeling Molecular Biology Monitor Parasites Participant Pathogenicity Pathway Analysis Patients Pattern recognition receptor Pharmaceutical Preparations Pharmacology Pharmacotherapy Policies Population Distributions Populations at Risk Predisposition Prevalence Principal Investigator Prognostic Marker Quantitative Evaluations Reaction Time Receptor Signaling Registries Regulation Research Personnel Research Project Grants Research Training Resistance Respondent Risk Role Sampling Screening procedure System Target Populations Therapeutic Training Programs Translating Treatment Effectiveness Treatment Failure Treatment outcome Variant Vector Ecology Vision Work Zoonoses authority base career cell type design eosinophil follow-up improved in vivo innovation monocyte multidisciplinary national surveillance neutrophil novel predictive marker profiles in patients programs receptor expression relapse risk response standard of care statistical and machine learning therapy outcome tool transcriptome treatment response vector

项目摘要

OVERVIEW SUMMARY Our TMRC program “Optimizing surveillance and treatment for control of cutaneous leishmaniasis”constitutes a concerted transdisciplinary and intersectorialeffort to address fundamental constraints on the control of cutaneous leishmaniasis in Colombia and the Latin American Region. Control of zoonotic cutaneous leishmaniasis is centered on case identification and treatment. However, the dispersed distribution of the populations at risk, underreporting, unavailability of information on the effectiveness of treatments administered, and increasing rates of treatment failure and evidence of drug resistance to the few available antileishmanial drugs undermine and subvert control efforts. The Goal of the TMRC “Optimizing Surveillance and Treatment for Control of Cutaneous Leishmaniasis” will be developed at three inter-related levels of response to treatment: Host innate responses affecting outcome of treatment and corresponding biomarkers; Parasite-dependent factors in drug susceptibility and therapeutic outcome; Active detection of affected Communities, cases and treatment follow-up. 1. To address critical knowledge gaps in the targeting and evaluation of interventions for control of cutaneous leishmaniasis. 2. To determine the relation of parasite susceptibility to anti-leishmanial drugs with the clinical and parasitological response to standard-of-care treatment, and parasite factors defining this relationship. 3. Identify innate host functions that contribute to cure or failure during antileishmanial drug therapy and their related biomarkers. This Center Program will be developed by a multidisciplinary team of national and international investigators that includes recognized experts, mid-career and new investigators in the relevant fields: Epidemiology, Vector Ecology, Molecular Biology and Genomics, Immunology and Cell Biology. The Principal Investigators and Core Leaders have already worked together successfully. Each brings high level specialized capacities to the corresponding projects and together, provide a broad scope of vision to the TMRC. Each Research Project will contribute to more effective control by addressing information and knowledge gaps and barriers to opportune, appropriate treatment to achieve cure, decrease the risk of relapse and by providing information and tools to reduce the prevalence and consequences of cutaneous leishmaniasis. CIDEIM is a WHO Collaborating Center for Leishmaniasis since 1992. The scope and focus of proposed TMRC program on the optimization of surveillance and treatment will be synergistic with our role as a WHOCC allowing the TMRC research and training program to channel and amplify capacity building within the Region and to translate findings to the competent national authorities

概述摘要我们的TMRC计划“优化监视和治疗皮肤利什曼病”构成了一致的跨学科和层间病，旨在解决基本的问题对哥伦比亚和拉丁美洲地区皮肤利什曼病的控制的限制。控制人畜共患病利什曼病以病例识别和治疗为中心。但是，分散了分配处于风险，报告不足的信息的分布，有关有效性的信息的不可用给药的治疗以及第二次治疗失败率和耐药性的证据可用的抗精神药物破坏并颠覆控制工作。 TMRC的目标“优化将在三个相互关联的情况下开发对皮肤利什曼病的监视和治疗” 对治疗的反应水平：宿主先天反应影响治疗结果和相应生物标志物；药物敏感性和治疗结果中的寄生虫依赖性因素；主动检测影响社区，病例和治疗随访。 1。解决干预措施的针对和评估控制的关键知识差距皮肤利什曼病。 2。确定寄生虫对抗脊髓药物的敏感性与临床和对护理标准治疗的寄生虫反应以及定义这种关系的寄生虫因素。 3。确定有助于治愈或失败期间治愈或失败的先天宿主功能他们相关的生物标志物。该中心计划将由国家和国际调查员的多学科团队开发其中包括公认的专家，职业中期和相关领域的新调查员：流行病学，向量生态学，分子生物学和基因组学，免疫学和细胞生物学。主要调查员和核心领导者已经成功合作。每个都为高水平的专业能力带来相应的项目并共同为TMRC提供了广泛的愿景范围。每个研究项目将通过解决信息和知识差距以及机会的障碍来为更有效的控制做出贡献，适当的治疗以实现治愈，降低退休风险，并通过提供信息和工具减少皮肤利什曼病的患病率和后果。 Cideim是WHO合作中心自1992年以来为利什曼病。提议的TMRC计划的范围和重点监视和治疗将与我们作为WHOCC的角色协同作用，允许进行TMRC研究和培训计划以引导和扩大该地区内能力建设并将发现转化为主管国家当局